

Guillaume Butler-Laporte

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/185508/publications.pdf>

Version: 2024-02-01

45
papers

2,142
citations

471061

17
h-index

276539

41
g-index

56
all docs

56
docs citations

56
times ranked

4022
citing authors

#	ARTICLE	IF	CITATIONS
1	Mapping the human genetic architecture of COVID-19. <i>Nature</i> , 2021, 600, 472-477.	13.7	640
2	Comparison of Saliva and Nasopharyngeal Swab Nucleic Acid Amplification Testing for Detection of SARS-CoV-2. <i>JAMA Internal Medicine</i> , 2021, 181, 353.	2.6	269
3	A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity. <i>Nature Medicine</i> , 2021, 27, 659-667.	15.2	188
4	Vitamin D and COVID-19 susceptibility and severity in the COVID-19 Host Genetics Initiative: A Mendelian randomization study. <i>PLoS Medicine</i> , 2021, 18, e1003605.	3.9	91
5	Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19. <i>Nature Genetics</i> , 2022, 54, 125-127.	9.4	75
6	<i>Staphylococcus aureus</i> bacteraemia mortality: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 1076-1084.	2.8	73
7	Diagnostic accuracy of serum (1-3)- β -D-glucan for <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2020, 26, 1137-1143.	2.8	72
8	Pan-ancestry exome-wide association analyses of COVID-19 outcomes in 586,157 individuals. <i>American Journal of Human Genetics</i> , 2021, 108, 1350-1355.	2.6	72
9	Age-dependent impact of the major common genetic risk factor for COVID-19 on severity and mortality. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	72
10	Rare loss-of-function variants in type I IFN immunity genes are not associated with severe COVID-19. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	56
11	Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment. <i>European Respiratory Journal</i> , 2015, 46, 1461-1470.	3.1	39
12	Novel genes and sex differences in COVID-19 severity. <i>Human Molecular Genetics</i> , 2022, 31, 3789-3806.	1.4	38
13	Adjunctive Daptomycin in the Treatment of Methicillin-susceptible <i>Staphylococcus aureus</i> Bacteremia: A Randomized, Controlled Trial. <i>Clinical Infectious Diseases</i> , 2021, 72, e196-e203.	2.9	34
14	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. <i>Science Advances</i> , 2021, 7, eabj5629.	4.7	32
15	The relative contributions of obesity, vitamin D, leptin, and adiponectin to multiple sclerosis risk: A Mendelian randomization mediation analysis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1994-2000.	1.4	31
16	MRSA colonization status as a predictor of clinical infection: A systematic review and meta-analysis. <i>Journal of Infection</i> , 2018, 77, 489-495.	1.7	27
17	Non-invasive diagnosis of <i>Pneumocystis jirovecii</i> pneumonia: a systematic review and meta-analysis. <i>Clinical Microbiology and Infection</i> , 2022, 28, 23-30.	2.8	22
18	Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity. <i>Human Genetics</i> , 2022, 141, 147-173.	1.8	22

#	ARTICLE	IF	CITATIONS
19	Remdesivir and systemic corticosteroids for the treatment of COVID-19: A Bayesian re-analysis. <i>International Journal of Infectious Diseases</i> , 2021, 104, 671-676.	1.5	21
20	Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia. Reply.. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	20
21	Enhancing medical studentsâ€™ education and careers in global surgery. <i>Canadian Journal of Surgery</i> , 2014, 57, 224-225.	0.5	19
22	Low-Dose TMP-SMX in the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: A Systematic Review and Meta-analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa112.	0.4	19
23	Using MRSA Screening Tests To Predict Methicillin Resistance in <i>Staphylococcus aureus</i> Bacteremia. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 7444-7448.	1.4	14
24	Genetic Determinants of Antibody-Mediated Immune Responses to Infectious Diseases Agents: A Genome-Wide and HLA Association Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa450.	0.4	12
25	Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis. <i>Mycoses</i> , 2021, 64, 1098-1110.	1.8	11
26	The effect of angiotensin-converting enzyme levels on COVID-19 susceptibility and severity: a Mendelian randomization study. <i>International Journal of Epidemiology</i> , 2021, 50, 75-86.	0.9	10
27	<i>Staphylococcus aureus</i> bacteremia mortality across country income groups: A secondary analysis of a systematic review. <i>International Journal of Infectious Diseases</i> , 2022, 122, 405-411.	1.5	10
28	Increasing Rates of Penicillin Sensitivity in <i>Staphylococcus aureus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	9
29	On the Treatment of <i>Pneumocystis jirovecii</i> Pneumonia: Current Practice Based on Outdated Evidence. <i>Open Forum Infectious Diseases</i> , 2021, 8, ofab545.	0.4	9
30	What Is the Optimal Follow-up Length for Mortality in <i>Staphylococcus aureus</i> Bacteremia? Observations From a Systematic Review of Attributable Mortality. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofac096.	0.4	9
31	Screening swabs surpass traditional risk factors as predictors of MRSA bacteremia. <i>BMC Infectious Diseases</i> , 2018, 18, 270.	1.3	8
32	Daptomycin versus placebo as an adjunct to beta-lactam therapy in the treatment of <i>Staphylococcus aureus</i> bacteremia: study protocol for a randomized controlled trial. <i>Trials</i> , 2018, 19, 297.	0.7	7
33	How generalizable are randomized controlled trials (RCTs) in <i>Staphylococcus aureus</i> bacteremia? A description of the mortality gap between RCTs and observational studies. <i>Clinical Infectious Diseases</i> , 2022, , .	2.9	7
34	Real-world Time to Positivity of 2 Widely Used Commercial Blood Culture Systems in Patients With Severe Manifestations of Sepsis: An Analysis of the FABLED Study. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa371.	0.4	5
35	Targeted caspofungin prophylaxis for invasive aspergillosis in high-risk liver transplant recipients, a single-center experience. <i>Transplant Infectious Disease</i> , 2021, 23, e13568.	0.7	4
36	Voriconazole therapeutic drug monitoring among lung transplant recipients receiving targeted therapy for invasive aspergillosis. <i>Clinical Transplantation</i> , 2022, 36, e14709.	0.8	4

#	ARTICLE	IF	CITATIONS
37	Using VRE screening tests to predict vancomycin resistance in enterococcal bacteremia. <i>Infection Control and Hospital Epidemiology</i> , 2020, 41, 425-429.	1.0	3
38	A recurrent hydatid cyst of the thigh diagnosed 13 years after initial presentation. <i>IDCases</i> , 2018, 11, 12-15.	0.4	2
39	Clinical Trials Increase Off-Study Drug Use: A Segmented Time-Series Analysis. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa449.	0.4	2
40	Tocilizumab versus the Covid19 tempest: Allâ€™s well that ends well or much ado about nothing?. <i>Clinical Microbiology and Infection</i> , 2021, 27, 158-159.	2.8	2
41	Using MRSA Screening Tests to Predict Methicillin Resistance in <i>Staphylococcus aureus</i> Bacteremia. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	1
42	Handheld infrared thermometer to evaluate cellulitis: the HI-TEC study. <i>Clinical Microbiology and Infection</i> , 2021, 27, 1814-1819.	2.8	1
43	Voriconazole Therapeutic Drug Monitoring Among Lung Transplant Recipients Receiving Targeted Therapy for Invasive Aspergillosis. <i>Open Forum Infectious Diseases</i> , 2016, 3, .	0.4	0
44	Reply to Volpicelli et al. <i>Clinical Infectious Diseases</i> , 2021, 73, 168-169.	2.9	0
45	Antibiotic treatment duration for bacteraemic pneumonia. <i>Lancet, The</i> , 2021, 398, 1485.	6.3	0